Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics (NASDAQ: VKTX) appointed Dorothy Gemmell to its Board of Directors, effective immediately. Gemmell brings more than 25 years of leadership experience across healthcare, digital health and commercialization, including prior roles as president or chief commercial officer at GoodRx, Capsule and Havas Life.
According to Viking, she has led growth initiatives, scaled organizations and developed revenue models across payer, provider, employer and pharmaceutical markets, and advises venture- and private equity-backed companies on commercialization strategies. Management highlights her appointment as the company advances its metabolic pipeline and prepares for VK2735’s potential launch, aiming to strengthen commercialization capabilities.
Viking Therapeutics (NASDAQ: VKTX) will release its second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company will host a conference call the same day at 4:30 p.m. Eastern Time to review the results and provide corporate updates.
Investors can join by phone using U.S. and international dial-in numbers or listen via a live webcast on Viking’s investor relations website. A telephone replay will be available until August 5, 2026, and a webcast archive will remain online for 30 days.
Viking Therapeutics (NASDAQ:VKTX) has begun a Phase 1 single ascending dose study of VK3019, a dual amylin and calcitonin receptor agonist, in healthy adults with BMI ≥30. The randomized, double-blind, placebo-controlled trial assesses safety, tolerability, pharmacokinetics, and exploratory effects on body weight.
VK3019 expands Viking’s obesity pipeline, which includes Phase 3 VANQUISH trials of injectable dual GLP-1/GIP agonist VK2735, planned Phase 3 work on oral VK2735, and advanced programs VK2809 for NASH and VK0214 for X-ALD.
Viking Therapeutics (NASDAQ: VKTX) appointed Hubert C. Chen, M.D. as chief medical officer, reporting to CEO Brian Lian. He will oversee clinical development, medical, and regulatory affairs as Viking advances late-stage programs, including potential commercialization of obesity candidate VK2735.
Dr. Chen brings more than two decades of biotech leadership across drug discovery, clinical development, regulatory strategy, and product approvals in metabolic and endocrine disorders, including prior C-level roles at Loyal Animal Health, Forte Biosciences, Metacrine, and Pfenex.
Viking Therapeutics (NASDAQ:VKTX) will present at two June 2026 investor conferences: the William Blair 46th Annual Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York.
Management will host a corporate presentation, breakout session, fireside chat, and investor meetings, with a live webcast and replay for the Jefferies fireside chat.
Viking Therapeutics (NASDAQ: VKTX) presented 13-week Phase 2 VENTURE-Oral/Venture-2 data for once-daily oral VK2735 in adults with obesity at ECO 2026.
VK2735 produced statistically significant, dose-dependent weight loss up to 12.2% (26.6 lbs), with early, progressive reductions from Week 1 and a generally favorable tolerability profile. A related Phase 3 subcutaneous study (VANQUISH-1) design was also highlighted.
Viking Therapeutics (NASDAQ: VKTX) will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) in Istanbul, May 12–15, 2026. One poster reports 13-week Phase 2 VENTURE-Oral efficacy and safety data; the other describes Phase 3 VANQUISH-1 design and enrollment demographics for subcutaneous VK2735.
Both posters are on display May 12–15 at Istanbul Congress Center Level B5, with a networking session on May 14 from 18:00–19:15 Turkey Time; presenter: Karen Modesto, M.D., VP Clinical Development.
Viking (Nasdaq: VKTX) reported Q1 2026 results and clinical progress on April 29, 2026. Key items: VK2735 VANQUISH-1 fully enrolled (>4,500 patients) and VANQUISH-2 fully enrolled (~1,000 patients); oral Phase 3 for VK2735 expected 4Q26. IND filed for amylin agonist VK3019 with Phase 1 planned in 2Q26. Cash, cash equivalents and short-term investments were $603 million at March 31, 2026. R&D expense was $150.2M and net loss was $158.3M for Q1 2026.
Viking Therapeutics (NASDAQ: VKTX) will release first-quarter 2026 financial results after market close on Wednesday, April 29, 2026. A conference call to discuss results and corporate updates will begin at 4:30 p.m. ET the same day.
Live webcast access is available via Viking's Webcasts page. A telephone replay is accessible until May 6, 2026, and an archived webcast will remain on the Webcasts page for 30 days.
Viking Therapeutics (NASDAQ: VKTX) will attend multiple investor conferences in April 2026, holding management 1-on-1 meetings with investors and analysts. Events and dates: Raymond James Biotech/BioPharma Conference on April 14, 2026 in New York, and Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston.